{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:44:42Z","timestamp":1791409482787,"version":"4.3.3"},"reference-count":214,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1928,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/modpathol.2017.58","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T07:42:02Z","timestamp":1498808522000},"page":"1338-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms"],"prefix":"10.1016","volume":"30","author":[{"given":"Arantza","family":"Onaindia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2017.58_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.seminhematol.2014.05.004","article-title":"Evolving understanding of the CLL genome","volume":"51","author":"Gruber","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1038\/modpathol.2017.58_bib2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1038\/modpathol.2017.58_bib3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN guidelines insights: non-Hodgkin's lymphomas, version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1038\/modpathol.2017.58_bib5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.6004\/jnccn.2012.0128","article-title":"Waldenstr\u00f6m's macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2013","volume":"10","author":"Anderson","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1038\/modpathol.2017.58_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1038\/modpathol.2017.58_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1038\/modpathol.2017.58_bib8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib9","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2017.58_bib10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u2018CLL prognostic index\u2019: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib11","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.18632\/oncotarget.3101","article-title":"Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2017.58_bib13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Oscier","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib16","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis","volume":"89","author":"D\u00f6hner","year":"1997","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib18","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib19","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib21","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"97","author":"Guarini","year":"2012","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/geno.1996.0201","article-title":"Genomic organization of the ATM gene","volume":"33","author":"Uziel","year":"1996","journal-title":"Genomics"},{"key":"10.1038\/modpathol.2017.58_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature04866","article-title":"ATM stabilizes DNA double-strand-break complexes during V(D)J recombination","volume":"442","author":"Bredemeyer","year":"2006","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V99.1.300","article-title":"Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage","volume":"99","author":"Stankovic","year":"2002","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib28","doi-asserted-by":"crossref","first-page":"e22356","DOI":"10.1371\/journal.pone.0022356","article-title":"cIAP1\/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4)","volume":"6","author":"Bertrand","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1038\/modpathol.2017.58_bib29","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1038\/modpathol.2017.58_bib31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","article-title":"Clinical implications of the molecular genetics of chronic lymphocytic leukemia","volume":"98","author":"Foa","year":"2013","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib32","doi-asserted-by":"crossref","first-page":"e1000518","DOI":"10.1371\/journal.pbio.1000518","article-title":"Non-canonical NF-\u03baB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2","volume":"8","author":"Conze","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1038\/modpathol.2017.58_bib33","doi-asserted-by":"crossref","first-page":"e1002502","DOI":"10.1371\/journal.pbio.1002502","article-title":"Correction: Non-canonical NF-\u03baB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2","volume":"14","author":"Conze","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1038\/modpathol.2017.58_bib34","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-\u03baB pathway genes in splenic marginal zone lymphoma","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib35","doi-asserted-by":"crossref","first-page":"435983","DOI":"10.1155\/2014\/435983","article-title":"Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go","volume":"2014","author":"Puiggros","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1038\/modpathol.2017.58_bib36","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Mart\u00ednez-Trillos","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib41","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib42","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.semcdb.2012.01.016","article-title":"Therapeutic approaches to modulating Notch signaling: current challenges and future prospects","volume":"23","author":"Groth","year":"2012","journal-title":"Semin Cell Dev Biol"},{"key":"10.1038\/modpathol.2017.58_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cger.2015.08.006","article-title":"Chronic lymphocytic leukemia and other lymphoproliferative disorders","volume":"32","author":"Wall","year":"2016","journal-title":"Clin Geriatr Med"},{"key":"10.1038\/modpathol.2017.58_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.58_bib46","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib47","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"D\u00f6hner","year":"1995","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/modpathol.2017.58_bib49","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib50","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2017.58_bib52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib54","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib56","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.12539","article-title":"Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia","volume":"163","author":"Jethwa","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib58","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"10.1038\/modpathol.2017.58_bib59","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States","volume":"54","author":"Liu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2017.58_bib60","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1002\/ajh.23314","article-title":"Survival outcomes with and without splenectomy in splenic marginal zone lymphoma","volume":"87","author":"Olszewski","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1038\/modpathol.2017.58_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","volume":"44","author":"Perrone","year":"2016","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2017.58_bib62","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib63","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Mart\u00ednez","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib64","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib65","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0046-8177(99)90031-X","article-title":"Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant?","volume":"30","author":"Lloret","year":"1999","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2017.58_bib66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1532\/IJH97.05017","article-title":"Blastic transformation after splenectomy in a patient with nonvillous splenic marginal zone lymphoma with p53 overexpression: a case report","volume":"81","author":"Kakinoki","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1038\/modpathol.2017.58_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-4608(03)00242-5","article-title":"Uncommon cytogenetic findings in a case of splenic marginal zone lymphoma with aggressive clinical course","volume":"148","author":"Viaggi","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1038\/modpathol.2017.58_bib68","doi-asserted-by":"crossref","first-page":"18504","DOI":"10.1074\/jbc.272.29.18504","article-title":"Two potent nuclear localization signals in the gut-enriched Kr\u00fcppel-like factor define a subfamily of closely related Kr\u00fcppel proteins","volume":"272","author":"Shields","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1038\/modpathol.2017.58_bib69","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib70","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2141.2011.08868.x","article-title":"High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies","volume":"155","author":"Boyd","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib72","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2169\/internalmedicine.54.2944","article-title":"Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens","volume":"54","author":"Okada","year":"2015","journal-title":"Intern Med"},{"key":"10.1038\/modpathol.2017.58_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1038\/modpathol.2017.58_bib74","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","article-title":"The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma","volume":"158","author":"Hockley","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib76","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.58_bib78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib79","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib80","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib81","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib82","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/PAI.0000000000000020","article-title":"Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction","volume":"22","author":"Jim\u00e9nez","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/modpathol.2017.58_bib83","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1038\/bcj.2014.4","article-title":"Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma","volume":"4","author":"Ansell","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1038\/modpathol.2017.58_bib84","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/modpathol.3800237","article-title":"Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes","volume":"18","author":"Thelander","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2017.58_bib85","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib86","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib87","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjh.13361","article-title":"MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity","volume":"169","author":"Schmidt","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib88","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib89","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2017.58_bib91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2017.58_bib92","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib93","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib94","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib95","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib96","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/leu.2013.194","article-title":"Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs","volume":"27","author":"Cirstea","year":"2013","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib97","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib98","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/blood.V74.5.1796.1796","article-title":"Four new recurring translocations in non-Hodgkin lymphoma","volume":"74","author":"Levine","year":"1989","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib99","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrc1409","article-title":"MALT lymphoma: from morphology to molecules","volume":"4","author":"Isaacson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2017.58_bib100","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","article-title":"MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma","volume":"101","author":"Sanchez-Izquierdo","year":"2003","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1172\/JCI25641","article-title":"cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas","volume":"116","author":"Hu","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1038\/modpathol.2017.58_bib102","doi-asserted-by":"crossref","first-page":"62627","DOI":"10.18632\/oncotarget.11548","article-title":"Recurrent mutations in NF-\u03baB pathway components, KMT2D, and NOTCH1\/2 in ocular adnexal MALT-type marginal zone lymphomas","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib103","doi-asserted-by":"crossref","first-page":"17038","DOI":"10.18632\/oncotarget.14928","article-title":"The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib104","first-page":"470","article-title":"Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection","volume":"90","author":"Traverse-Glehen","year":"2005","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib105","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib106","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1073\/pnas.1401952111","article-title":"Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis","volume":"111","author":"Ortiz","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.58_bib107","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib108","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/bcj.2015.89","article-title":"Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas","volume":"5","author":"Lunning","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1038\/modpathol.2017.58_bib109","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"10.1038\/modpathol.2017.58_bib110","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib111","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1038\/modpathol.2017.58_bib112","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"10.1038\/modpathol.2017.58_bib113","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.82.21.7439","article-title":"Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18","volume":"82","author":"Cleary","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"10.1038\/modpathol.2017.58_bib114","first-page":"93","article-title":"Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma","volume":"2","author":"Cotter","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2017.58_bib115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/ajcp\/103.4.472","article-title":"Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma","volume":"103","author":"Horsman","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2017.58_bib116","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"Salaverria","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib117","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","article-title":"Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern","volume":"100","author":"Ferreiro","year":"2015","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib118","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib119","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","article-title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults","volume":"118","author":"Salaverria","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib121","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.V99.6.1959","article-title":"Clinicopathologic analysis of follicular lymphoma occurring in children","volume":"99","author":"Lorsbach","year":"2002","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib122","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2012-05-429514","article-title":"Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement","volume":"120","author":"Louissaint","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib123","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2012.073916","article-title":"Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas","volume":"98","author":"Martin-Guerrero","year":"2013","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib124","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2016-03-703819","article-title":"Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene","volume":"128","author":"Schmidt","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib125","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","article-title":"Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations","volume":"128","author":"Louissaint","year":"2016","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib126","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2008-07-168682","article-title":"A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36","volume":"113","author":"Katzenberger","year":"2009","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib127","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/modpathol.2016.51","article-title":"Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36\/TNFRSF14 abnormalities, and STAT6 mutations","volume":"29","author":"Siddiqi","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2017.58_bib128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/modpathol.2017.58_bib129","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib130","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib131","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib132","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib133","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib134","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib135","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib136","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib137","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib138","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.58_bib139","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib140","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V76.10.2086.2086","article-title":"Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation","volume":"76","author":"Medeiros","year":"1990","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib141","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"10.1038\/modpathol.2017.58_bib142","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/315340a0","article-title":"Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation","volume":"315","author":"Tsujimoto","year":"1985","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib143","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"10.1038\/modpathol.2017.58_bib144","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib145","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib146","doi-asserted-by":"crossref","unstructured":"Correa JG, Cibeira MT, Tovar N et al, Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstr\u00f6m macroglobulinaemia. Br J Haematol 2016; 10.1111\/bjh.14266.","DOI":"10.1111\/bjh.14266"},{"key":"10.1038\/modpathol.2017.58_bib147","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.58_bib148","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2010-01-263806","article-title":"Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling","volume":"116","author":"Hartmann","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib149","first-page":"4365","article-title":"Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants","volume":"93","author":"Be\u00e0","year":"1999","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic hypermutation and V(H) gene usage in mantle cell lymphoma","volume":"68","author":"Thors\u00e9lius","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib151","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib152","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib153","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","article-title":"The biology of human lymphoid malignancies revealed by gene expression profiling","volume":"87","author":"Staudt","year":"2005","journal-title":"Adv Immunol"},{"key":"10.1038\/modpathol.2017.58_bib154","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib156","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1038\/modpathol.2017.58_bib157","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib158","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib159","doi-asserted-by":"crossref","first-page":"86433","DOI":"10.18632\/oncotarget.13239","article-title":"Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib160","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib161","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib162","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","article-title":"MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome","volume":"22","author":"Rovira","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib163","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib164","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib165","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib166","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","article-title":"Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas","volume":"317","author":"Weiss","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2017.58_bib167","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"22","author":"Klapper","year":"2008","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib168","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/gcc.22391","article-title":"Novel IGH and MYC translocation partners in diffuse large B-cell lymphomas","volume":"55","author":"Otto","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/modpathol.2017.58_bib169","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1038\/modpathol.2017.58_bib170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-\u03baB in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1038\/modpathol.2017.58_bib171","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib172","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"key":"10.1038\/modpathol.2017.58_bib173","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib174","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling","volume":"11","author":"Lam","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib175","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdf185","article-title":"p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas","volume":"13","author":"Leroy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2017.58_bib176","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428190410001713170","article-title":"Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature","volume":"45","author":"Kerbauy","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2017.58_bib177","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3109\/10428194.2010.502584","article-title":"PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma","volume":"51","author":"Liu","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2017.58_bib178","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib179","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1073\/pnas.0607286103","article-title":"Structural basis for understanding oncogenic p53 mutations and designing rescue drugs","volume":"103","author":"Joerger","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/modpathol.2017.58_bib180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)97001-8","article-title":"Structural biology of the tumor suppressor p53 and cancer-associated mutants","volume":"97","author":"Joerger","year":"2007","journal-title":"Adv Cancer Res"},{"key":"10.1038\/modpathol.2017.58_bib181","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.onc.1202314","article-title":"Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy","volume":"18","author":"Blandino","year":"1999","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2017.58_bib182","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1913","article-title":"Assessing p53 in clinical contexts: unlearned lessons and new perspectives","volume":"208","author":"Hall","year":"2006","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2017.58_bib184","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/path.1704","article-title":"What have animal models taught us about the p53 pathway?","volume":"205","author":"Lozano","year":"2005","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2017.58_bib185","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib186","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.hemonc.2016.05.006","article-title":"Detection of t(8;14) c-myc\/IgH gene rearrangement by long-distance polymerase chain reaction in patients with diffuse large B-cell lymphoma","volume":"9","author":"Kiaei","year":"2016","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1038\/modpathol.2017.58_bib187","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAS.0000000000000758","article-title":"Mantle cell lymphoma with MYC rearrangement: a report of 17 patients","volume":"41","author":"Hu","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2017.58_bib188","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2008.07152.x","article-title":"MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis","volume":"142","author":"Huh","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2017.58_bib189","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5858\/2003-127-0305-MBCLWM","article-title":"Mature B-cell leukemias with more than 55% prolymphocytes: report of 2 cases with Burkitt lymphoma-type chromosomal translocations involving c-myc","volume":"127","author":"Merchant","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/modpathol.2017.58_bib190","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.MP.0000037310.82136.99","article-title":"Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features","volume":"15","author":"Hao","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2017.58_bib191","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2005-01-0168","article-title":"Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas","volume":"106","author":"Bellan","year":"2005","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib192","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/gcc.20345","article-title":"IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination","volume":"45","author":"Guikema","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/modpathol.2017.58_bib193","doi-asserted-by":"crossref","first-page":"224","DOI":"10.18632\/oncotarget.4399","article-title":"Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas","volume":"7","author":"Piccaluga","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib194","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.58_bib195","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.58_bib196","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.726","article-title":"Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells","volume":"3","author":"Sander","year":"2012","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2017.58_bib197","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1038\/modpathol.2017.58_bib198","doi-asserted-by":"crossref","first-page":"pe25","DOI":"10.1126\/scisignal.3134pe25","article-title":"B cell receptor signaling: picky about PI3Ks","volume":"3","author":"Limon","year":"2010","journal-title":"Sci Signal"},{"key":"10.1038\/modpathol.2017.58_bib199","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2017.58_bib200","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"key":"10.1038\/modpathol.2017.58_bib201","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1038\/modpathol.2017.58_bib203","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"Van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib204","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2400736","article-title":"Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes","volume":"11","author":"Linke","year":"1997","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib205","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/sj.leu.2401172","article-title":"Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas","volume":"12","author":"Pott","year":"1998","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib206","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2017.58_bib207","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jmoldx.2016.07.009","article-title":"Methodologic considerations in the application of next-generation sequencing of human TRB repertoires for clinical use","volume":"19","author":"Xu","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1038\/modpathol.2017.58_bib208","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib209","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib210","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib211","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2017.58_bib212","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2017.58_bib213","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"10.1038\/modpathol.2017.58_bib214","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/321702a0","article-title":"A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells","volume":"321","author":"Bentley","year":"1986","journal-title":"Nature"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol201758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201758","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222012364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222012364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/modpathol.2017.58","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:46:59Z","timestamp":1760230019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222012364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":214,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0893395222012364"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2017.58","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2017.58","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}